

**Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute**

**Clinical Features of the Prostate Clinical Research Information Systems (CRIS) Database**

<b>Clinical Features of Patients with Complete New Patient Information (N=5391)</b>	
<b>Feature</b>	<b>Value</b>
<b>Mean age at Diagnosis</b>	66 (36-95)
<b>Years (range)</b>	
<b>Ethnicity</b>	
White	4817 (89%)
Other/Unknown	334 (6%)
African American	200 (4%)
Asian	39 (<1)
American Indian	3 (<1)
<b>Mean PSA Level at Dx</b>	38 (0-10,366)
<b>ng/mL (range)</b>	
<b>Median PSA Level at Dx</b>	6.3(0-10,366)
<b>ng/mL (range)</b>	
<b>Clinical Stage at Dx</b>	
T1	2312 (53%)
T2	912 (20 %)
T3	153 (4%)
T4	5 (<1%)
T(any)N1 M0	46 (1%)
T(any)N(any) M1	174 (4%)
Other	722 (17%)
<b>Gleason Score at Dx</b>	
GS 2- 6	1901 (40%)
GS 7	1786 (37%)
GS 8-10	1121 (23%)
<b>Trigger For Dx</b>	
Increase PSA	3522 (73%)
Abnormal DRE	445 (9%)
Benign Prostatic Hyperplasia	170 (4%)
Other	37 (1%)
Pain	55 (1%)
Hematuria	30 (<1%)
Missing	548 (11%)

**Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute**

**Clinical Features of the Prostate Clinical Research Information Systems (CRIS) Database**

<b>Disease and Treatment Status at Time of First Visit</b>	
<b>Disease Status</b>	<b>N (%)</b>
Localized CaP/High risk	794 (15)
Localized CaP/Intermediate risk	1246 (23)
Localized CaP/Low risk	1642 (30)
Rising PSA post local Rx	526 (10)
Mets, on primary hormones-refractory	385 (7)
Mets, on primary hormones-remission	201 (4)
No Dx of CaP	77 (1)
No Mets, on primary hormones-refractory	112 (2)
No Mets, on primary hormones-remission	113 (2)
No Rx for Mets	59 (1)
Missing	209 (4)
<b>Treatment Status</b>	<b>N (%)</b>
No previous CaP Rx	3301 (61)
Receiving neoadjuvant Rx	211 (4)
Completed neoadjuvant Rx	15 (<1)
Receiving localized Rx	15 (<1)
Completed localized Rx	539 (10)
Receiving adjuvant Rx	18 (<1)
Completed adjuvant Rx	53 (1)
Receiving salvage local Rx	14 (<1)
Completed salvage local Rx	94 (2)
Receiving primary hormone Rx for advanced disease	458 (8)
Receiving secondary hormone Rx for advanced disease	180 (3)
Receiving chemo for advanced disease	83 (1)
Other cancer Rx	24 (<1)
Palliative care only	10 (<1)
Missing	378 (7)

<b>Patients Registered to Protocol 01-045 as of 9/28/2007</b>			
<b>01-045</b>	<b>Blood Samples</b>	<b>Frozen Tissue</b>	<b>Blood and Tissue</b>
4,590	3,603	841	730

**Clinical Features of the  
Renal Clinical Research Information Systems (CRIS) Database**

<b>Clinical Features of Patients with Complete New Patient Information</b>	
<b>Feature</b>	<b>Value</b>
<b>Mean age at Diagnosis</b>	58 (12-91)
<b>Years (range)</b>	
<b>Ethnicity</b>	
White	936 (88%)
Other/Unknown	93 (8%)
African American	32 (3%)
Asian	9 (1%)
<b>Clinical Stage at Dx</b>	
T1	125 (44%)
T2	63 (22%)
T3	99 (35%)
T4	2 (<1%)
T(any) N1 M0	4 (1%)
<b>Trigger For Dx</b>	
No symptom, found CT/MRI/XR	45 (36%)
Blood in urine	20 (16%)
Body pain	27 (22%)
Other	20 (16%)
Mass/abdominal swelling	1 (<1%)
No symptom, found other	3 (1%)

**Clinical Features of the  
Renal Clinical Research Information Systems (CRIS) Database**

<b>Disease and Treatment Status at Time of First Visit of RCC Patients</b>	
<b>Disease Status</b>	<b>N (%)</b>
Localized Renal Cell Cancer	83 (32)
Locally Advanced RCC	15 (6)
Metastatic Disease, Complete Remission	4 (2)
Metastatic Disease, Not Measurable	3 (1)
Metastatic Disease, Partial Remission	2 (1)
Metastatic Disease, Progressing	99 (38)
Metastatic Disease, Stable	39 (15)
No Dx of RCC	9 (3)
Unknown	7 (2)
<b>Treatment Status</b>	<b>N (%)</b>
No Previous RCC Rx	98 (37)
Completed Localized Rx of Primary Tumor	69 (26)
Completed Resection or Ablation of Met Disease	25 (25)
Receiving Radiation RX for Metastatic Disease	3 (1)
Completed Radiation Rx for Metastatic Disease	8 (3)
Receiving Systemic Rx	28 (11)
Completed Systemic Rx	3 (1)
Palliative care only	1 (<1)
Missing	27 (10)

Read about recently completed genitourinary oncology projects at  
<http://www.dfci.org/pat/adult/genitourinary-cancer/recently-completed-genitourinary-oncology-projects.html>

For more information, please email William Oh, MD, at [William\\_Oh@dfci.harvard.edu](mailto:William_Oh@dfci.harvard.edu).